A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma [2]

Leukemia and Lymphoma

Volumn 46, Issue 6, 2005, Pages 945-947

  Hönemann, Dirk ^a   Prince, H Miles ^a   Seymour, John F ^a   Wolf, Max M ^a   Westerman, David ^a   Januszewicz, E Henry ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ANAPHYLAXIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LETTER; MALE; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 21844464295     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500057684     Document Type: Letter

References (12)

1. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-1356.
2. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33:86-89.
3. Boccadoro M, Palumbo A, Bringhen S et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002;87:846-850.
4. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588-596.
5. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
6. Uziely B, Jeffers S, Isacson R et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-1785.
7. Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer 2004;100:2052-2063.
8. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
9. Moloney M, Prince HM, Seymour JF et al. Incidence and predictors of infusion related reactions to liposomal anthracyclines in patients with haematologic malignancies. Proc Haematol Soc Aust NZ 86.
10. Dimopoulos MA, Pouli A, Zervas K et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003;14:1039-1044.
11. Hussein MA, Wood L, Hsi E et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002;95:2160-2168.
12. Tsiara SN, Kapsali E, Christou L, Panteli A, Pritsivelis N, Bourantas KL. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data. Eur J Haematol 2000;65:118-122.